HAIFA, ISRAEL, May 4, 2015 — Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PLTR), a leading developer of placenta-based cell therapy products, today announced that its executives will present at the following regenerative medicine and finance conferences during the month of May:
International Society for Pharmaceutical Engineering Europe Annual Conference Date: 9:10 a.m. on Wednesday, May 6 2015
Location: Frankfurt, Germany
Presentation Title: Flexible Manufacturing of Cell Therapy Product, Challenges and Possible Solutions
Presented by: Nadav Eshkol, Team Leader, Process Development
Israel Advanced Technology Industries Biomed Israel 2015 Date: 5:10 p.m. on Wednesday, May 13 2015
Location: Tel Aviv, Israel
Presentation Title: Regenerative Medicine – When Placental Cells Meet Technology Presented by: Yaky Yanay, President & COO
Oppenheimer’s 16th Annual Israeli Conference Date: Sunday, May 10 2015
Location: Tel Aviv, Israel
Presentation by: Zami Aberman, Chairman & CEO
Hong Kong-Israel “Game Changing” Investments Date: Wednesday, May 20 2015
Locations: Hong Kong
Presentation by: Yaky Yanay, President & COO
2015 Capvision “Internet+” Healthcare Investment Summit Date: Thursday, May 21 2015
Location: Beijing, China
Presentation by: Yaky Yanay, President & COO
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company’s patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company’s proprietary three- dimensional expansion technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.
Contact:
Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109
